Article in The Journal of experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Kelsey A TothDepartment of Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-8536-4628
Erica G SchmittDepartment of Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-8878-0619
Ana KolicheskiDepartment of Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-7084-5119
Zev J GreenbergDepartment of Pediatrics, Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-6234-7005
Elizabeth LevendoskyDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-6230-1851
Nermina SaucierDepartment of Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0009-0004-8992-1427
Kelsey TrammelDepartment of Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0009-0002-3560-5619
Vasileios OikonomouFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.ORCID 0000-0002-7553-0159
Michail S LionakisFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.ORCID 0000-0003-4994-9500
Eynav KlechevskyDepartment of Pathology and Immunology, Division of Immunobiology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-6121-1571
Brian S KimKimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, Precision Immunology Institute, Friedman Brain Institute, Mark Lebwohl Center for Neuroinflammation and Sensation, New York, NY, USA.ORCID 0000-0002-8100-7161
Laura G SchuettpelzDepartment of Pediatrics, Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-6047-3641
Naresha SaligramaDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-2526-7150
Megan A CooperDepartment of Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-5696-172X
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Washington University DDRCC Supplemental Equipment RequestP30DK052574 · NIDDK · WASHINGTON UNIVERSITY · PI Nicholas O. Davidson · 2000 to 2026
$30.8M
Immunopathogenesis of Fungal InfectionsZIAAI001175 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LIONAKIS, MICHAIL · 2012 to 2025
$23.9M
STAT3 variants as a rheostat of immune toleranceP01AI155393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mark S Anderson · 2022 to 2026
$10.5M
Viral Discovery in Rheumatoid ArthritisP30AR048335 · NIAMS · WASHINGTON UNIVERSITY · PI WEIHL, CONRAD C · 2001 to 2015
$8.9M
Washington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Alfred Hyoungju Kim · 2018 to 2026
$7.6M
Child Health Research CenterK12HD076224 · NICHD · WASHINGTON UNIVERSITY · PI MARK E. LOWE · 2013 to 2026
$6.2M
TRAINING IN REGENERATIVE MEDICINET32EB028092 · NIBIB · WASHINGTON UNIVERSITY · PI Farshid Guilak · 2020 to 2026
$2.0M
The Role of CD5 in Tumor ImmunityR01CA245277 · NCI · WASHINGTON UNIVERSITY · PI KLECHEVSKY, EYNAV YAFIT · 2020 to 2024
$1.8M
Harnessing Human Dendritic Cell Subsets in Skin for the Design of Novel ImmunotherapiesR01AR075959 · NIAMS · WASHINGTON UNIVERSITY · PI KLECHEVSKY, EYNAV YAFIT · 2019 to 2023
$1.7M
Division of Intramural Research of the NIAIDNational Institute of Allergy and Infectious DiseasesNCI NIH HHS P30 CA091842NCI NIH HHS P30 CA91842NCI NIH HHS R01 CA245277NCRR NIH HHSNIAID NIH HHS P01 AI155393NIAMS NIH HHS P30 AR048335NIAMS NIH HHS P30 AR073752NIAMS NIH HHS R01 AR075959NIBIB NIH HHS T32 EB028092NICHD NIH HHS K12 HD076224NIDDK NIH HHS P30 DK052574NIH HHS 1P01AI155393Scleroderma FoundationSiteman Cancer CenterSt. Louis Children's HospitalWashington University P30DK052574Washington University Rheumatic Diseases Research Resource-based Center P30AR073752
6 · The paper itself
Abstract
Germline gain-of-function (GOF) variants in STAT3 cause an inborn error of immunity associated with early-onset poly-autoimmunity and immune dysregulation. To study tissue-specific immune dysregulation, we used a mouse model carrying a missense variant (p.G421R) that causes human disease. We observed spontaneous and imiquimod (IMQ)-induced skin inflammation associated with cell-intrinsic local Th17 responses in STAT3 GOF mice. CD4+ T cells were sufficient to drive skin inflammation and showed increased Il22 expression in expanded clones. Certain aspects of disease, including increased epidermal thickness, also required the presence of STAT3 GOF in epithelial cells. Treatment with a JAK inhibitor improved skin disease without affecting local Th17 recruitment and cytokine production. These findings collectively support the involvement of Th17 responses in the development of organ-specific immune dysregulation in STAT3 GOF and suggest that the presence of STAT3 GOF in tissues is important for disease and can be targeted with JAK inhibition.
Indexed as
DermatitisGain of Function MutationInflammationSkinSTAT3 Transcription FactorTh17 CellsAnimalsCD4-Positive T-LymphocytesHumansImiquimodInterleukin-22MiceMice, Inbred C57BLImiquimodInterleukin-22STAT3 protein, humanSTAT3 Transcription Factor
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A human STAT3 gain-of-function variant drives local Th17 dysregulation and skin inflammation in mice. · full record | OpenQuestion